<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873911</url>
  </required_header>
  <id_info>
    <org_study_id>RDCRNLDN6707</org_study_id>
    <secondary_id>U54NS065768</secondary_id>
    <nct_id>NCT01873911</nct_id>
  </id_info>
  <brief_title>Neurobehavioral Phenotypes in MPS III</brief_title>
  <official_title>Characterizing the Neurobehavioral Phenotype(s) in MPS III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National MPS Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shire Human Genetic Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis #1: Factor analysis of the revised Sanfilippo Behavior Rating Scale (SBRS) will
      identify a group of externalizing behaviors and a group of Kl端ver-Bucy syndrome-like
      behaviors as two different factors that are at least partially independent.

      Hypothesis #2a: Children with MPS III will show more hyperlocomotion, fearlessness,
      asociality and noncompliance than children of similar cognitive ability with MPS I.

      Hypothesis #2b: These behaviors will become more frequent and/or intensify over time,
      consistent with the Cleary and Wraith (1993) model. Quantifying them will provide a more
      empirical framework for staging disease progression.

      Hypothesis #3: Brain volumetric analysis and diffusion-tensor imaging will reveal
      abnormalities of frontal and temporal lobe structures that will correlate with externalizing
      and Kl端ver-Bucy syndrome-like behaviors, respectively.

      Hypothesis #4. Loss of cognitive and language function as measures of neurologic decline will
      directly precede or co-vary with behavioral decline.

      The primary objective of this study is to identify the behavioral phenotype and its neural
      basis in MPS III (Sanfilippo syndrome). Is the behavioral phenotype similar to that of
      Kl端ver-Bucy syndrome, and is there evidence for amygdala abnormality? The secondary objective
      of this research study is to develop easily administered, sensitive and specific
      neurobehavioral and neuroimaging markers to characterize the behavioral phenotype(s) of MPS
      III; to track their progression; and to delineate their neural substrates. Such markers are
      critical for identifying the stage of disease for each patient, and to measure treatment
      outcome. Although we know that severe cognitive decline is one essential characteristic of
      MPS III, the other highly salient characteristic is a range of abnormal and disruptive
      behaviors that can include, but go well beyond, childhood noncompliance and oppositionality.
      These behaviors set Sanfilippo syndrome apart from the other MPS disorders. They cause major
      disruption in the child's familial, school, and community environments. Delineating these
      behavioral abnormalities will help in better understanding the neurological disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Like some other mucopolysaccharidosis (MPS) syndromes, MPS III (Sanfilippo syndrome) is
      characterized by a severe cognitive decline ending in dementia and death. Unlike other MPS
      syndromes, earlier-stage MPS III is also associated with a range of abnormal and disruptive
      behaviors that can include, but go well beyond, childhood noncompliance and oppositionality.
      These behaviors, which cause major disruption in the child's familial, school, and community
      environments, set MPS III apart from the other MPS disorders. These behaviors may also
      indicate the identity of the neural pathways affected in this disease; their sequence of
      onsets may indicate the order in which these pathways are affected. We propose to define and
      categorize the behavioral profile(s) or phenotype(s) of MPS III and correlate them with
      clinical quantitative neuroimaging in order to understand the neural bases of the disease. In
      addition, we will use these results to develop a set of sensitive and specific measures that
      can be easily administered by health care professionals to help monitor the disease and the
      efficacy of future treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Temperament</measure>
    <time_frame>Within One Year of Enrollment</time_frame>
    <description>Using Risk Room procedures of the established &quot;Laboratory Temperament Assessment Battery&quot; (Lab-TAB), the investigators will measure and record each subject's startle, exploration (fear), compliance, and attachment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>Within One Year of Enrollment</time_frame>
    <description>Assessments of research subjects' quality of life will be made using age-appropriate standardized assessment tools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Related Potentials Measurement</measure>
    <time_frame>Within One Year of Enrollment</time_frame>
    <description>High-density Event-Related Potentials (ERPs) will be elicited and recorded. ERPs provide information about the timing and location of neurocognitive processes associated with the individual's processing of discrete stimuli. Two sets of stimuli will be used: 1. auditory stimuli consisting of non-language sounds and phonemes; and 2. visual stimuli consisting of images of emotional faces. All stimuli will be presented in an oddball paradigm format (repetition of stimuli with a random insertion of a novel stimulus).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging Examination</measure>
    <time_frame>Within One Year of Enrollment</time_frame>
    <description>To examine the neural substrate of MPS III behavioral phenotypes of participating research subjects, the investigators will perform high-resolution brain volumetric magnetic resonance imaging (MRI) during clinical scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cognitive Development</measure>
    <time_frame>Within One Year of Enrollment</time_frame>
    <description>Research subjects' cognitive development will be assessed using age-appropriate standardized assessment tools.</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Sanfilippo Syndrome Type A</condition>
  <condition>Sanfilippo Syndrome Type B</condition>
  <condition>Hurler Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty children who have been diagnosed with MPS III type A or type B. Ten age-matched
        children (as controls) who have been diagnosed with MPS I (Hurler syndrome), who in the
        past have undergone hematopoietic cell transplantation, and who have been
        clinically-determined to have low cognitive function.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Research Subjects: Verified diagnosis of MPS IIIA or MPS IIIB (having proof of either
        genetic mutation or enzymatic analysis prior to enrollment in this study); must be between
        the ages of 2 and 12 years; must be able to walk.

        Control group: Verified diagnosis of MPS IH; must have already undergone hematopoietic cell
        transplantation in the past; must be aged between 2 and 5 years; and must be able to walk
        without support.

        Exclusion Criteria:

        Participants will be excluded who are unable to cooperate or comply with this study's
        procedures; in the opinion of the principal investigator, participants who have other
        severely-limiting co-existing conditions such as severe hearing or visual impairment, will
        be excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsa G Shapiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Potegal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rarediseasesnetwork.epi.usf.edu/</url>
    <description>Rare Diseases Clinical Research Network</description>
  </link>
  <link>
    <url>http://www.mpssociety.org/</url>
    <description>National MPS Society</description>
  </link>
  <reference>
    <citation>Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child. 1993 Sep;69(3):403-6. Review.</citation>
    <PMID>8215557</PMID>
  </reference>
  <reference>
    <citation>Meyer A, Kossow K, Gal A, M端hlhausen C, Ullrich K, Braulke T, Muschol N. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics. 2007 Nov;120(5):e1255-61. Epub 2007 Oct 15.</citation>
    <PMID>17938166</PMID>
  </reference>
  <reference>
    <citation>Jha S, Patel R. Kluver-Bucy syndrome -- an experience with six cases. Neurol India. 2004 Sep;52(3):369-71.</citation>
    <PMID>15472430</PMID>
  </reference>
  <reference>
    <citation>Angrilli A, Mauri A, Palomba D, Flor H, Birbaumer N, Sartori G, di Paola F. Startle reflex and emotion modulation impairment after a right amygdala lesion. Brain. 1996 Dec;119 ( Pt 6):1991-2000.</citation>
    <PMID>9010003</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS IIIA</keyword>
  <keyword>MPS IIIB</keyword>
  <keyword>Sanfilippo syndrome type A</keyword>
  <keyword>Sanfilippo syndrome type B</keyword>
  <keyword>Hurler syndrome</keyword>
  <keyword>cognitive decline</keyword>
  <keyword>MPS IH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

